PanCareSurPass Project HL7 FHIR Implementation Guide
0.2.0 - CI Build 150

PanCareSurPass Project HL7 FHIR Implementation Guide, published by PanCareSurPass Project. This guide is not an authorized publication; it is the continuous build for version 0.2.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/pcsp/ and changes regularly. See the Directory of published versions

ValueSet: Risk Factors

Official URL: http://hl7.eu/fhir/ig/pcsp/ValueSet/vs-riskfactor-eu-pcsp Version: 0.2.0
Draft as of 2025-09-03 Computable Name: RiskFactor

Risk Factors used by the PCSP algorithm

References

Logical Definition (CLD)

 

Expansion

Expansion performed internally based on codesystem Risk Factors v0.2.0 (CodeSystem)

This value set contains 112 concepts

CodeSystemDisplayDefinition
  1.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the thyroid glandRT to a vol exposing the thyroid gland
  1.2http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspTBITBI
  1.3http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspMIBG therapy (I-131 MIBG therapy)MIBG therapy (I-131 MIBG therapy)
  2.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT >= 10 Gy to a vol exposing the breastsRT >= 10 Gy to a vol exposing the breasts
  2.2http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspOR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young ageOR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age
  3.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT >= 35 Gy to a vol exposing the heartRT >= 35 Gy to a vol exposing the heart
  3.2http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspAnthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2
  3.3http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2
  4.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspAlkylating agentsAlkylating agents
  4.2http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the testesRT to a vol exposing the testes
  4.3http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspIncluding TBIIncluding TBI
  5.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT >=12 Gy to a vol exposing the testiclesRT >=12 Gy to a vol exposing the testicles
  6.3http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspSurgery to the spinal cord, sympathetic nerves or pelvisSurgery to the spinal cord, sympathetic nerves or pelvis
  6.4http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspHypogonadalHypogonadal
  7.2http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the ovariesRT to a vol exposing the ovaries
  8.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT >= 30 Gy to a vol exposing the head or the brainRT >= 30 Gy to a vol exposing the head or the brain
  8.2http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspCisplatin (with or without carboplatin > 1500 mg/m2)Cisplatin (with or without carboplatin > 1500 mg/m2)
  9.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the pancreasRT to a vol exposing the pancreas
  10.2http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspHSCTHSCT
  11.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a volume exposing the hypothalamus or pituatary glandRT to a volume exposing the hypothalamus or pituatary gland
  11.3http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspHypothalamic or pituitary tumourHypothalamic or pituitary tumour
  11.4http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspNeurosurgery of the hypothalamus or pituitary glandNeurosurgery of the hypothalamus or pituitary gland
  12.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the kidneys, heart and associated large vesselsRT to a vol exposing the kidneys, heart and associated large vessels
  12.3http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspNephrectomyNephrectomy
  12.4http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspIfosfamideIfosfamide
  12.5http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspPlatinium based chemotherapyPlatinium based chemotherapy
  12.6http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspNitrosureasNitrosureas
  12.7http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspImmunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)
  13.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspCranial and/or spinal RTCranial and/or spinal RT
  13.3http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspMethotrexateMethotrexate
  13.4http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspGonadal failureGonadal failure
  13.5http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspGrowth hormone deficiencyGrowth hormone deficiency
  13.6http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspProlonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatmentProlonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment
  13.7http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspHSCT, especially with an history of GVHDHSCT, especially with an history of GVHD
  14.3http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspHigh dose RTHigh dose RT
  15.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRadiotherapy to a vol exposing the HP region >= 30 GyRadiotherapy to a vol exposing the HP region >= 30 Gy
  15.2http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspSurgery near or within the HP regionSurgery near or within the HP region
  15.3http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspCNS tumours near or within the HP regionCNS tumours near or within the HP region
  16.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRadiotherapy to a vol exposing the HP region< 30 GyRadiotherapy to a vol exposing the HP region< 30 Gy
  16.2http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspHydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD)Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD)
  17.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRadiotherapy to a vol exposing the HP regionRadiotherapy to a vol exposing the HP region
  17.5http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsphydrocephalus or cerebrospinal fluid shunthydrocephalus or cerebrospinal fluid shunt
  19.3http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRadioiodine therapy (I-131 ablation therapy)Radioiodine therapy (I-131 ablation therapy)
  19.5http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspAllogenic HSCTAllogenic HSCT
  19.6http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspTotal thyroidectomyTotal thyroidectomy
  20.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the head, brain or neckRT to a vol exposing the head, brain or neck
  21.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspHistory of a central nervous system tumorHistory of a central nervous system tumor
  21.2http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the brain ANY DOSERT to a vol exposing the brain ANY DOSE
  21.4http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspBrain surgeryBrain surgery
  21.5http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspHigh dose cytarabine IV (intravenous)High dose cytarabine IV (intravenous)
  21.6http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspHigh dose MTX IVHigh dose MTX IV
  21.7http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspAny Chemotherapy IT (intrathecal)Any Chemotherapy IT (intrathecal)
  22.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspVinca-AlkaloidsVinca-Alkaloids
  22.2http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspCisplatin or carboplatinCisplatin or carboplatin
  23.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the lensRT to a vol exposing the lens
  24.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the eye and orbitRT to a vol exposing the eye and orbit
  25.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the craniofacial area, especially after high doses and at a young ageRT to a vol exposing the craniofacial area, especially after high doses and at a young age
  25.3http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspSurgery to the face, especially at a young ageSurgery to the face, especially at a young age
  26.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspSurgery of the spineSurgery of the spine
  26.2http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspSurgery of the chest (Does not include CVC pose)Surgery of the chest (Does not include CVC pose)
  26.3http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the spineRT to a vol exposing the spine
  26.4http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspSpinal or paraspinal malignanciesSpinal or paraspinal malignancies
  27.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspCyclophosphamideCyclophosphamide
  27.3http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the bladderRT to a vol exposing the bladder
  27.5http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspCystectomyCystectomy
  27.6http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspHysterectomyHysterectomy
  27.7http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspPelvic surgeryPelvic surgery
  27.8http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspSpinal cord surgerySpinal cord surgery
  28.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the uterus only femaleRT to a vol exposing the uterus only female
  29.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the oral cavity or salivary glandsRT to a vol exposing the oral cavity or salivary glands
  29.4http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspChemotherapyChemotherapy
  30.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the gastro-intestinal tractRT to a vol exposing the gastro-intestinal tract
  30.3http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspOesophageal surgeryOesophageal surgery
  30.4http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspAbdominal surgeryAbdominal surgery
  30.5http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspWith a history of chronic GVHDWith a history of chronic GVHD
  31.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspAnthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2
  32.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the lungsRT to a vol exposing the lungs
  32.3http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspBleomycinBleomycin
  32.4http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspBusulfanBusulfan
  32.5http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspBCNU CarmustineBCNU Carmustine
  32.6http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspCCNU LomustineCCNU Lomustine
  32.7http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspThoracic surgeryThoracic surgery
  33.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspCisplatin Any doseCisplatin Any dose
  33.2http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspIfosfamide Any doseIfosfamide Any dose
  33.3http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspCarboplatin Any doseCarboplatin Any dose
  34.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a volume exposing the liverRT to a volume exposing the liver
  34.10http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspChronic GVHDChronic GVHD
  34.11http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspLiver surgeryLiver surgery
  34.3http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspHSCT (irrespective of GVHD)HSCT (irrespective of GVHD)
  34.5http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspMercaptopurine ThioguanineMercaptopurine Thioguanine
  34.6http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspDactinomycinDactinomycin
  34.8http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspChronic viral hepatitisChronic viral hepatitis
  34.9http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspSinusoidal obstruction syndromeSinusoidal obstruction syndrome
  35.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspHSCT (irrespective of GVHD)HSCT (irrespective of GVHD)
  35.2http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspMultiple red blood cell transfusionsMultiple red blood cell transfusions
  36.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspSplenectomySplenectomy
  36.2http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT >= 10 Gy to a vol exposing the spleenRT >= 10 Gy to a vol exposing the spleen
  36.3http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspAllogenic HSCT (with or without TBI)Allogenic HSCT (with or without TBI)
  36.4http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspAutologus HSCT conditioned with TBIAutologus HSCT conditioned with TBI
  37.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspHereditary cancer sdHereditary cancer sd
  38.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspAny RT including TBI (predominantly in the RT field)Any RT including TBI (predominantly in the RT field)
  38.2http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspHSCT Especially with a history of skin GvHDHSCT Especially with a history of skin GvHD
  39.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the colon and rectumRT to a vol exposing the colon and rectum
  40.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the oral cavityRT to a vol exposing the oral cavity
  41.2http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspAnthracyclines and/or MitoxantroneAnthracyclines and/or Mitoxantrone
  41.3http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspEpipodophyllotoxins or autologousEpipodophyllotoxins or autologous
  41.4http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspAutologous haematopoietic stem cell transplantAutologous haematopoietic stem cell transplant
  42.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspCiclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)
  45.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the head or brainRT to a vol exposing the head or brain
  46.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT between 15 and 35 Gy to a vol exposing the heartRT between 15 and 35 Gy to a vol exposing the heart
  46.2http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspAnthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2
  47.1http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcspRT to a vol exposing the kidney or urinary tractRT to a vol exposing the kidney or urinary tract

Explanation of the columns that may appear on this page:

Level A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies
System The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code The code (used as the code in the resource instance)
Display The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition An explanation of the meaning of the concept
Comments Additional notes about how to use the code